{"id":66996,"date":"2026-06-01T20:19:47","date_gmt":"2026-06-01T12:19:47","guid":{"rendered":"https:\/\/flcube.com\/?p=66996"},"modified":"2026-06-01T20:19:48","modified_gmt":"2026-06-01T12:19:48","slug":"cttqs-egfr-c-met-bispecific-adc-tqb6411-shows-44-response-rate-in-heavily-pretreated-solid-tumors-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66996","title":{"rendered":"CTTQ&#8217;s EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong>, a subsidiary of <strong>Sino Biopharmaceutical Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>)<\/strong>, presented <strong>first-in-human Phase I clinical data<\/strong> for <strong>TQB6411<\/strong>, an in-house developed <strong>Category 1 drug candidate<\/strong>, in patients with <strong>advanced solid tumors<\/strong> at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong>. The <strong>EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC)<\/strong> demonstrated compelling efficacy with a <strong>44.4% objective response rate (ORR)<\/strong> and <strong>100% disease control rate (DCR)<\/strong> in the \u22654 mg\/kg dose group, including <strong>significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients<\/strong> with up to three prior therapy lines.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dose Group<\/th><th>Patients Evaluated<\/th><th>Partial Responses<\/th><th>ORR<\/th><th>DCR<\/th><th>Notable NSCLC Responses<\/th><\/tr><\/thead><tbody><tr><td><strong>\u22654 mg\/kg (combined)<\/strong><\/td><td>9<\/td><td>4<\/td><td><strong>44.4%<\/strong><\/td><td><strong>100%<\/strong><\/td><td>Multiple significant tumor reductions<\/td><\/tr><tr><td><strong>5.3 mg\/kg<\/strong><\/td><td>1 NSCLC patient (2 prior lines)<\/td><td>1<\/td><td>100%<\/td><td>100%<\/td><td><strong>55.2% target lesion reduction<\/strong><\/td><\/tr><tr><td><strong>4.0 mg\/kg<\/strong><\/td><td>2 NSCLC patients (\u22653 prior lines)<\/td><td>2<\/td><td>100%<\/td><td>100%<\/td><td><strong>30.4% and 48.1% target lesion reductions<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-study-design-amp-safety-profile\" class=\"wp-block-heading\">Study Design &amp; Safety Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Identifier<\/strong>: NCT07043751<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: 26 patients with advanced solid tumors<\/li>\n\n\n\n<li><strong>Dose Escalation<\/strong>: 0.8 mg\/kg \u2192 6.6 mg\/kg across five dose levels<\/li>\n\n\n\n<li><strong>Safety Milestone<\/strong>: <strong>No dose-limiting toxicities (DLTs)<\/strong> observed through maximum tested dose<\/li>\n\n\n\n<li><strong>Treatment-Related Adverse Events (TRAEs)<\/strong>:<\/li>\n\n\n\n<li>Grade 3 TRAEs: <strong>21.7%<\/strong> (5\/23 patients with \u226521 days follow-up)<\/li>\n\n\n\n<li>Grade \u22654 TRAEs: <strong>0%<\/strong> in overall population<\/li>\n\n\n\n<li><strong>Pulmonary Safety<\/strong>: <strong>No interstitial lung disease (ILD)<\/strong> reported, addressing key concern with EGFR-targeting agents<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-competitive-differentiation\" class=\"wp-block-heading\">Drug Profile &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: <strong>TQB6411<\/strong> \u2013 <strong>EGFR\/c-MET bispecific antibody-drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Target Rationale<\/strong>: Dual targeting of <strong>EGFR and c-MET<\/strong> pathways addresses resistance mechanisms in solid tumors<\/li>\n\n\n\n<li><strong>Innovative Design<\/strong>: <strong>c-MET-biased affinity<\/strong> reduces development risks while creating differentiated competitive advantage<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Leverages well-established target combination with novel bispecific ADC format<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Category 1 new drug candidate (first-in-class designation in China)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-clinical-implications\" class=\"wp-block-heading\">Strategic Clinical Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase I data reveals several critical advantages for TQB6411:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Heavily Pretreated Population<\/strong>: Demonstrates efficacy in patients with <strong>2\u20133+ prior therapy lines<\/strong>, addressing significant unmet need<\/li>\n\n\n\n<li><strong>NSCLC Focus<\/strong>: Strong activity in <strong>non-small cell lung cancer<\/strong>, where EGFR\/c-MET co-expression drives resistance<\/li>\n\n\n\n<li><strong>Safety Leadership<\/strong>: Absence of ILD and low grade 3+ toxicity rates differentiate from existing EGFR inhibitors<\/li>\n\n\n\n<li><strong>Dose Optimization<\/strong>: Maximum tolerated dose not reached at 6.6 mg\/kg, suggesting potential for further dose escalation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This first-in-human data validates our c-MET-biased bispecific ADC approach,&#8221; said Dr. Wang Li, Chief Executive Officer of CTTQ. &#8220;The combination of robust efficacy in heavily pretreated patients with an exceptionally clean safety profile, particularly the absence of interstitial lung disease, positions TQB6411 as a promising candidate for further development in EGFR\/c-MET co-expressing solid tumors.&#8221;<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-outlook\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The results position TQB6411 to address substantial markets in oncology:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Population<\/strong>: <strong>EGFR\/c-MET co-expressing tumors<\/strong> represent significant subsets of NSCLC, gastric, and other solid tumors<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: First bispecific ADC targeting this combination with clinical proof-of-concept<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Data supports international regulatory filings and partnership opportunities<\/li>\n\n\n\n<li><strong>Revenue Projection<\/strong>: Analysts estimate peak annual sales potential of <strong>$800 million\u2013$1.2 billion<\/strong> if Phase II\/III confirms efficacy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view the <strong>44% ORR in heavily pretreated patients<\/strong> as highly competitive, particularly given the favorable safety profile that could enable combination strategies and broader patient eligibility.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for TQB6411. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100014_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060100014_c.\"><\/object><a id=\"wp-block-file--media-ed42dd16-ade0-46eb-9389-b49d1ac7f4c3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100014_c.pdf\">2026060100014_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100014_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ed42dd16-ade0-46eb-9389-b49d1ac7f4c3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,16,661,17,908,313],"class_list":["post-66996","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-cancer","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-results","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CTTQ&#039;s EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66996\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTTQ&#039;s EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66996\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T12:19:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T12:19:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CTTQ&#8217;s EGFR\\\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026\",\"datePublished\":\"2026-06-01T12:19:47+00:00\",\"dateModified\":\"2026-06-01T12:19:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996\"},\"wordCount\":538,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"Cancer\",\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial results\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66996#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66996\",\"name\":\"CTTQ's EGFR\\\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T12:19:47+00:00\",\"dateModified\":\"2026-06-01T12:19:48+00:00\",\"description\":\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\\\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\\\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66996\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66996#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CTTQ&#8217;s EGFR\\\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CTTQ's EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66996","og_locale":"en_US","og_type":"article","og_title":"CTTQ's EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026","og_description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.","og_url":"https:\/\/flcube.com\/?p=66996","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T12:19:47+00:00","article_modified_time":"2026-06-01T12:19:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66996#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66996"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CTTQ&#8217;s EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026","datePublished":"2026-06-01T12:19:47+00:00","dateModified":"2026-06-01T12:19:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66996"},"wordCount":538,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","ADC \/ XDC","Cancer","Chia Tai Tianqing Pharmaceutical","Clinical trial results","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66996#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66996","url":"https:\/\/flcube.com\/?p=66996","name":"CTTQ's EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T12:19:47+00:00","dateModified":"2026-06-01T12:19:48+00:00","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented first-in-human Phase I clinical data for TQB6411, an in-house developed Category 1 drug candidate, in patients with advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EGFR\/c-MET-targeting bispecific antibody-drug conjugate (ADC) demonstrated compelling efficacy with a 44.4% objective response rate (ORR) and 100% disease control rate (DCR) in the \u22654 mg\/kg dose group, including significant tumor reductions in heavily pretreated non-small cell lung cancer (NSCLC) patients with up to three prior therapy lines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66996#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66996"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66996#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CTTQ&#8217;s EGFR\/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66996"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66996\/revisions"}],"predecessor-version":[{"id":66998,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66996\/revisions\/66998"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}